- Home
- AVTX vs EDSA Comparison
AVTX vs EDSA Comparison
Compare AVTX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- EDSA
- Stock Information
- Founded
- AVTX 2011
- EDSA 2015
- Country
- AVTX United States
- EDSA Canada
- Employees
- AVTX N/A
- EDSA N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- EDSA Health Care
- Exchange
- AVTX Nasdaq
- EDSA Nasdaq
- Market Cap
- AVTX 248.3M
- EDSA 18.6M
- IPO Year
- AVTX 2015
- EDSA N/A
- Fundamental
- Price
- AVTX $18.03
- EDSA $1.86
- Analyst Decision
- AVTX Strong Buy
- EDSA Strong Buy
- Analyst Count
- AVTX 9
- EDSA 2
- Target Price
- AVTX $30.14
- EDSA $13.00
- AVG Volume (30 Days)
- AVTX 372.4K
- EDSA 898.7K
- Earning Date
- AVTX 11-07-2025
- EDSA 12-12-2025
- Dividend Yield
- AVTX N/A
- EDSA N/A
- EPS Growth
- AVTX N/A
- EDSA N/A
- EPS
- AVTX N/A
- EDSA N/A
- Revenue
- AVTX $441,000.00
- EDSA N/A
- Revenue This Year
- AVTX N/A
- EDSA N/A
- Revenue Next Year
- AVTX N/A
- EDSA N/A
- P/E Ratio
- AVTX N/A
- EDSA N/A
- Revenue Growth
- AVTX N/A
- EDSA N/A
- 52 Week Low
- AVTX $3.39
- EDSA $1.55
- 52 Week High
- AVTX $19.41
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- AVTX 68.08
- EDSA 31.75
- Support Level
- AVTX $16.77
- EDSA $1.90
- Resistance Level
- AVTX $19.01
- EDSA $2.94
- Average True Range (ATR)
- AVTX 1.50
- EDSA 0.21
- MACD
- AVTX 0.09
- EDSA -0.09
- Stochastic Oscillator
- AVTX 77.30
- EDSA 9.15
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.